A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

This study is testing a combination of three drugs — decitabine, lisaftoclax, and olverembatinib — in people with advanced chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML) that is no longer responding to standard targeted therapies. **You may be eligible if...** - You are 18 or older - You have advanced CML (accelerated or blast phase) or Ph+ AML that has relapsed or is treatment-resistant - You have tried and failed or could not tolerate at least one standard targeted therapy (BCR-ABL inhibitor) - Your heart, liver, kidney, and pancreatic function are within acceptable ranges **You may NOT be eligible if...** - You have previously received lisaftoclax or olverembatinib - You have had acute pancreatitis in the past year - You have serious heart failure or significant cardiovascular disease - You have active leukemia in the brain or spinal cord - You are HIV positive (unless well controlled on treatment) - You have active hepatitis B or C - You are pregnant or breastfeeding - You cannot swallow pills Talk to your doctor to see if this trial is right for you.